AllSci News
Roche reports Phase III miss for giredestrant in first-line breast cancer setting
Roche’s giredestrant misses primary endpoint in persevERA trial for ER-positive advanced breast cancer Roche announced that the Phase III persevERA Breast Cancer…
Servier’s USD 2.5b Day One Bio acquisition gives control of glioma drug Ojemda
Servier is moving to acquire US biotech Day One Biopharmaceuticals (Nasdaq: DAWN) for around USD 2.5 billion. The an all-cash transaction will…
Roche partner Zealand’s Phase II data for petrelintide shows placebo-like safety
Copenhagen-based Zealand Pharma announced positive petrelintide Phase II results from the ZUPREME-1 dose-finding trial, reporting up to 10.7% mean body weight reduction…
Erasca and Tango Therapeutics partner on ERAS-0015 and vopimetostat combination trial
US biopharma companies Erasca, Inc. and Tango Therapeutics entered a clinical trial collaboration and supply agreement to evaluate a combination of ERAS-0015,…
Alnylam looks to Tenaya for new RNAi cardiovascular target candidates in USD 1.2b deal
US-based biotechs Tenaya Therapeutics, Inc. (Nasdaq: TNYA) and Alnylam Pharmaceuticals (Nasdaq: ALNY) entered into a research collaboration agreement to discover and validate…
Theravance in crisis after Phase III ampreloxetine failure in MSA-related nOH
Theravance Biopharma announced that the Phase III CYPRESS study evaluating ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) associated with multiple…
Hutchmed advances ATTC platform with first-in-human trial of EGFR-targeted PI3K/PIKK conjugate
China-based biopharma HutchMed (Nasdaq/AIM:HCM;HKEX:13) announced the clinical debut of pipeline candidate HMPL-A580, an antibody-targeted therapy conjugate (ATTC) designed to deliver a PI3K/PIKK…
ISCT, JSRM launch 5-year collaboration on clinical iPSC therapies
The International Society for Cell & Gene Therapy (ISCT) and the Japanese Society for Regenerative Medicine (JSRM) announced a five-year strategic collaboration…
Prolium Bio launches with USD 50m Series A and China-licensed CD20 bispecific for autoimmune diseases
Prolium Bioscience, a New York-based clinical-stage biotechnology company focused on developing therapies for severe autoimmune diseases, has launched with USD 50 million…
UCB bags Antengene’s CD19/CD3 bispecific TCE for autoimmune diseases for up to USD 1.3b
Hong Kong-headquartered Antengene Corporation and Brussels-based UCB (Euronext Brussels) announced a global license agreement granting UCB worldwide exclusive rights to develop, manufacture,…
Theolytics secures EUR 8m Horizon Europe grant for trial of oncolytic virus in ovarian cancer
UK-based biotech Theolytics, a specialist in oncolytic immunotherapies, has been awarded EUR 8 million (USD 9.3 million) in non-dilutive grant funding from…
SNIPR Biome posts positive early data for CRISPR-armed phages against E. coli infection
Denmark-based SNIPR Biome announced publication of final Phase I results for SNIPR001, a CRISPR–Cas-armed bacteriophage cocktail designed to selectively kill Escherichia coli…
COUR Pharma reports one-year Phase IIa data for PLGA nanoparticle drug in primary biliary cholangitis
Chicago-based COUR Pharma announced one-year results from its Phase IIa study of CNP-104 in primary biliary cholangitis (PBC), reporting that two doses…
Esperion targets outpatient heart failure market with USD 255m Corstasis acquisition
Esperion Therapeutics (NASDAQ: ESPR) has agreed to acquire Corstasis Therapeutics, a privately held commercial-stage biopharmaceutical company, in a deal valued at up…
J&J’s nipocalimab bags 5th FDA Fast Track indication with nod for lupus
Johnson & Johnson (J&J; NYSE: JNJ) announced receipt of Fast Track designation from the US FDA for nipocalimab, an investigational anti-neonatal Fc…
The AllSci Brief
Systematic R&D and deal news. Daily.